GHRH, stabilised
Natural GHRH is cleared within minutes by DPP-4, the same enzyme that limits GLP-1. Tesamorelin keeps the active sequence and adds a modification at the N-terminus that blocks the cleavage site.
The design problem is the same one semaglutide solves at the other end of the catalogue, which is a reasonable illustration of how much peptide engineering comes down to protecting a working sequence from the enzymes that would otherwise remove it.
The N-terminus is the vulnerable end because that is where the enzyme cuts, taking the first residues and with them the ability to activate the receptor at all. Blocking that one site is a small change with a disproportionate consequence, and it is a pattern you meet again and again once you start reading how these molecules are built.
An approved indication, narrowly drawn
Tesamorelin was approved for the reduction of excess visceral adipose tissue in HIV-associated lipodystrophy. That is a specific condition with a specific mechanism, and the approval is scoped to it.
It is worth being precise about what that means. An approval demonstrates that the compound met defined endpoints in a defined population under regulatory scrutiny. It does not license every claim made about it since.
Readers asking what is tesamorelin usually want to know whether an approval makes a compound safer than its neighbours. It makes it better characterised, which is not the same claim: the registry entries on ClinicalTrials.gov record what was studied, in whom and against which endpoints, and that scope is exactly the scope the approval is confined to.
| Class | GHRH analogue |
| Modification | N-terminal, blocks DPP-4 cleavage |
| Approved indication | HIV-associated lipodystrophy |
| Regulatory status | Approved, unusual in this catalogue |
| Format | Pre-filled peptide pen |
| Purity | ≥ 99% (HPLC) |
| Evidence base | Completed clinical programme |
| Category | Research use only |
Batch and identity information, with no claim about effect.
Why it matters to the rest of this catalogue
Most GHRH-analogue discussion online concerns compounds that never reached that level of testing. Tesamorelin gives you a reference point: this is what the class looks like when it is put through a full programme.
Compare the depth of what is known here to what is known about the research-grade analogues, and the difference in evidence is immediately visible. That comparison is more useful than any argument we could make.
The cleanest version of that comparison is with the unmodified releasing-hormone fragment, which carries no protection against the enzyme whatsoever. Same receptor, same intent, an entirely different residence time in circulation, and a research record that reflects the difference.
What a tesamorelin approval does and does not license
An approval is a decision about one product, taken from one dossier, for one population and one endpoint. It travels badly. The moment a claim steps outside the studied indication it is no longer supported by the approval, even though the molecule has not changed by an atom, and this is the most common route by which regulatory language gets misused in this field.
What we supply is not that licensed product either. It is laboratory-grade peptide sold under the research use only classification, accompanied by a batch certificate rather than a patient information leaflet, and it carries none of the assurances a pharmacy product carries. Those two sentences are the whole of the distinction, and they matter more here than on pages where no approval exists to be confused with.
One further constraint applies regardless. Releasing-hormone analogues sit inside a prohibited category in sport, and an approved indication is not an exemption from it, the anti-doping page explains why a therapeutic use exemption is a narrow documented route arranged in advance rather than an argument made afterwards.
Tesamorelin in the catalogue
HPLC purity of 99% minimum, with the analysis available for your batch.
Where Tesamorelin fits in
Three neighbouring topics from the knowledge base.
About Tesamorelin
The things people check before buying.